Curis LifesciencesNSE:CURIS +0.40%19 ROE % is 21.75% as of Mar. 2026, which is 78% below its 10-year median of 98.84. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 935 Drug Manufacturers companies, Curis Lifesciences ranks better than 88.98% on this metric.
The historical rank and industry rank for Curis Lifesciences's ROE % or its related term are showing as below:
NSE:CURIS'
s ROE % Range Over the Past 10 Years
Min: 21.75 Med: 98.84 Max: 186.45
Current: 21.75
During the past 4 years, Curis Lifesciences's highest ROE % was 186.45%. The lowest was 21.75%. And the median was 98.84%.
NSE:CURIS's ROE % is ranked better than 88.98% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs NSE:CURIS: 21.75
Curis Lifesciences (NSE:CURIS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (Mar. 2026) net income data. The Revenue data used here is one times the annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Curis Lifesciences ROE % Related Terms
Curis Lifesciences ROE % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences ROE % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
ROE %
186.45
141.51
56.17
21.75
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
ROE %
186.45
141.51
56.17
21.75
NSE:CURIS vs ZTS, UTHR: ROE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's ROE % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Curis Lifesciences (NSE:CURIS) has a ROE % of 21.75% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Curis Lifesciences and its competitors. This is 78% below median its historical median of 98.84. Over the past decade, Curis Lifesciences' ROE % has ranged from 21.75 to 186.45. According to the industry distribution chart, Curis Lifesciences ranks #103 out of 935 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is Curis Lifesciences' ROE % too high?
Curis Lifesciences' current ROE % of 21.75% is 78% below median its 10-year median of 98.84. Over the past 10 years, this metric has ranged from a low of 21.75 to a high of 186.45. The Drug Manufacturers industry median ROE % is 6.00. Curis Lifesciences' value of 21.75% is 262.5% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #103 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #103 out of 935 companies for ROE %. This places Curis Lifesciences in the top 11% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. Curis Lifesciences' value of 21.75% is 262.5% above this benchmark. Historically, Curis Lifesciences' own ROE % has ranged from 21.75 to 186.45 over the past decade. While the company's 10-year median is 98.84 vs. the industry median of 6.00, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current ROE % of 21.75% is 262.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current ROE % is 21.75%, which is 78% below median its own 10-year median of 98.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current ROE % of 21.75%. The current ROE % is 21.75%, which is 78% below median its 10-year median of 98.84 and 262.5% above the Drug Manufacturers industry median of 6.00. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current ROE % is 21.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 